论文部分内容阅读
《美国医学会杂志.内科学》(JAMA Intern Med)2013年8月5日在线发表了一项研究,该项研究评价了绝经后女性应用不同级别的降压药与乳腺浸润性导管癌和乳腺浸润性小叶癌的相关性。结果表明,长期应用钙离子通道拮抗剂(CCB)与乳腺癌危险相关,该研究是首个发现长期应用CCB与乳腺癌危险关系的研究,尚需进一步的研究确证这一发现并评估潜在发生的生物学机制。该项基于人群的病例对照研究纳入了年龄在(55~74)岁的女性受试者,浸润性导管癌、乳腺浸润性小叶癌病例数分别为880和1027例,同时纳入856例无癌症受试者作为对照组。这些患者均在近期持续应用抗高血压药物。研究
A study published online August 5, 2013, JAMA Intern Med, evaluated the use of different classes of antihypertensive drugs in patients with postmenopausal women with invasive ductal breast and breast Invasive lobular carcinoma correlation. The results show that long-term use of calcium channel blockers (CCBs) is associated with breast cancer risk and is the first study to find long-term associations between CCB and breast cancer risk. Further research is needed to confirm this finding and to assess potential occurrence Biological mechanism. This population-based case-control study enrolled female subjects aged 55-74 years, with invasive ductal carcinoma and invasive lobular carcinoma of the breast at 880 and 1027, respectively, and enrolled 856 patients without cancer Tester as a control group. These patients are continuing to use antihypertensive drugs in the near future. the study